Endometrial Hyperplasia Developing in a Woman on Tamoxifen for Breast Cancer
Clinical Scenario
This protocol addresses endometrial hyperplasia that develops in a woman who is receiving tamoxifen as part of her breast cancer treatment. Women taking tamoxifen carry an increased risk of developing endometrial hyperplasia and cancer, making this a recognised and important clinical situation requiring specific management decisions.
Condition Context
Tamoxifen's uterine effects mean that new-onset endometrial hyperplasia in this setting requires both oncological and gynaecological input. Women on tamoxifen should be informed of these endometrial risks, and any new finding of hyperplasia warrants prompt evaluation.
Approach (partial overview)
Management involves re-evaluating the ongoing role of the current breast cancer therapy in collaboration with the treating oncologist, alongside classification-guided management of the hyperplasia itself. The full protocol details the decision pathway…
References
- Women taking tamoxifen should be informed about the increased risks of developing endometrial hyperplasia and cancer.
- The need for tamoxifen should be reassessed and management should be according to the histological classification of endometrial hyperplasia and in conjunction with the woman's oncologist.
- Therefore, the use of tamoxifen should be reassessed in conjunction with the woman's oncologist and an alternative treatment sought if appropriate.
View source ↗